Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04869137 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
A Phase 2 study of Merkel Cell Carcinoma and Neuroendocrine Carcinoma of the Skin, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT04869137: Active Phase 2 study of Merkel Cell Carcinoma and Neuroendocrine Carcinoma of the Skin, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT04869137 is a Phase 2 study of Merkel Cell Carcinoma and Neuroendocrine Carcinoma of the Skin that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 26 participants, below the 50-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04869137, a Phase 2 study of Merkel Cell Carcinoma and Neuroendocrine Carcinoma of the Skin, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.
Primary Outcome
Pathological Complete Response will be determined by pathologist examination of tissue after neoadjuvant treatment and resection
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib Oral Product
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-05-28 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT04869137 still lists
NCT04869137 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 50-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (48% lower).
The record links to 3 conditions, with Merkel Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04869137 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04869137 about?
NCT04869137 is a clinical study titled "Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma". This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.
What is the current status of trial NCT04869137?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2021-05-28. Estimated completion is 2026-09.
What conditions does trial NCT04869137 study?
This clinical trial studies the following conditions: Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin.
What interventions are being tested in trial NCT04869137?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib Oral Product (DRUG).
Who is sponsoring clinical trial NCT04869137?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04869137 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Merkel Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04869137's enrollment target sits among peer trials
26 17th of 26 higher than 10 of 26 other Merkel Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Merkel Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
RECRUITING · Phase 2
-
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI